She explained that the vaccine candidate has been developed for more than a year and it now goes through the first and second phases of combined clinical trials, TASS news agency reported.
Skvortsova stated that the vaccine candidate will be used to fight all SARS-CoV-2 strains because ‘its effectiveness does not depend on the transformations and mutations occurring in the spike protein on the surface of the virus.’
The FMBA head stressed that the new vaccine candidate will generate cell-mediated immunity, but also humoral immunity.
‘This has already been confirmed in preclinical trials and now in clinical trials,’ she concluded.
jg/iff/mgt/mml
